News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
In its first-quarter 2025 investor letter, Carillon Scout Mid Cap Fund highlighted stocks such as Hims & Hers Health, Inc.
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your ...
LOS ANGELES, June 23, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("H ...
Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at ...
MarketBeat on MSN18h
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...
In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback